Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance. / Kalsen, Anders; Hostrup, Morten; Karlsson, Sebastian; Hemmersbach, Peter; Bangsbo, Jens; Backer, Vibeke.
In: Journal of Applied Physiology, Vol. 117, No. 10, 2014, p. 1180-1187.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance
AU - Kalsen, Anders
AU - Hostrup, Morten
AU - Karlsson, Sebastian
AU - Hemmersbach, Peter
AU - Bangsbo, Jens
AU - Backer, Vibeke
N1 - CURIS 2014 NEXS 293
PY - 2014
Y1 - 2014
N2 - In a randomized double-blind crossover design, we investigated the effect of the beta2-agonist terbutaline on endurance performance and substrate utilization in nine moderately trained males (maximum oxygen uptake (VO2max): 58.9±3.1 mL min(-1) kg(-1)). Subjects performed 60 min of submaximal exercise (65-70% of VO2max) immediately followed by a 300-kcal time trial with inhalation of either terbutaline (TER) or placebo (PLA). Pulmonary gas exchange was measured during the submaximal exercise and muscle biopsies were collected before and after the exercise bouts. Time trial performance was not different between PLA and TER (1054±125 vs. 1072±145 s). During the submaximal exercise, respiratory exchange ratio, glycogen breakdown (PLA: 195±28; TER: 266±32 mmol kg dw(-1)) and muscle lactate accumulation (PLA: 13.2±1.2; TER: 20.3±1.6 mmol kg dw(-1)) were higher (P<0.05) with TER than PLA. There was no difference between PLA and TER in net muscle glycogen utilization and lactate accumulation during the time trial. IMTG did not change with treatment or exercise. PDH-E1α Ser(293) and Ser(300) phosphorylation were lower (P<0.05) before the submaximal exercise with TER than PLA with no difference after the submaximal exercise and the time trial. Before the submaximal exercise, ACC2 Ser(221) phosphorylation was higher (P<0.05) with TER than PLA. There was no difference in αAMPK Thr(172) phosphorylation between treatments. The present study suggests that beta2-agonists do not enhance 300-kcal time trial performance, but increase carbohydrate metabolism in skeletal muscles during submaximal exercise independent of AMPK and ACC phosphorylation, and that this effect diminishes as drug exposure time, exercise duration and intensity are increased.
AB - In a randomized double-blind crossover design, we investigated the effect of the beta2-agonist terbutaline on endurance performance and substrate utilization in nine moderately trained males (maximum oxygen uptake (VO2max): 58.9±3.1 mL min(-1) kg(-1)). Subjects performed 60 min of submaximal exercise (65-70% of VO2max) immediately followed by a 300-kcal time trial with inhalation of either terbutaline (TER) or placebo (PLA). Pulmonary gas exchange was measured during the submaximal exercise and muscle biopsies were collected before and after the exercise bouts. Time trial performance was not different between PLA and TER (1054±125 vs. 1072±145 s). During the submaximal exercise, respiratory exchange ratio, glycogen breakdown (PLA: 195±28; TER: 266±32 mmol kg dw(-1)) and muscle lactate accumulation (PLA: 13.2±1.2; TER: 20.3±1.6 mmol kg dw(-1)) were higher (P<0.05) with TER than PLA. There was no difference between PLA and TER in net muscle glycogen utilization and lactate accumulation during the time trial. IMTG did not change with treatment or exercise. PDH-E1α Ser(293) and Ser(300) phosphorylation were lower (P<0.05) before the submaximal exercise with TER than PLA with no difference after the submaximal exercise and the time trial. Before the submaximal exercise, ACC2 Ser(221) phosphorylation was higher (P<0.05) with TER than PLA. There was no difference in αAMPK Thr(172) phosphorylation between treatments. The present study suggests that beta2-agonists do not enhance 300-kcal time trial performance, but increase carbohydrate metabolism in skeletal muscles during submaximal exercise independent of AMPK and ACC phosphorylation, and that this effect diminishes as drug exposure time, exercise duration and intensity are increased.
U2 - 10.1152/japplphysiol.00635.2014
DO - 10.1152/japplphysiol.00635.2014
M3 - Journal article
C2 - 25257871
VL - 117
SP - 1180
EP - 1187
JO - Journal of Applied Physiology
JF - Journal of Applied Physiology
SN - 8750-7587
IS - 10
ER -
ID: 125184588